NEUROVIVE PHARMACEUTICAL AB Inactive Instrument
Company NeuroVive Pharmaceutical AB Swiss Exchange
Equities
NVP
SE0002575340
Biotechnology & Medical Research
Business Summary
Sales per Business
| SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Mitochondrial Diseases
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +341.94% |
Sales per region
| SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Sweden
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +341.94% |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
Ellen Donnelly
CEO | Chief Executive Officer | 50 | 03/21/03 |
Eskil Elmér
FOU | Founder | 54 | 01/00/01 |
| Director of Finance/CFO | 57 | 01/13/01 | |
Dag Nesse
CTO | Chief Tech/Sci/R&D Officer | - | 01/23/01 |
Magnus Hansson
CTO | Chief Tech/Sci/R&D Officer | 48 | 01/08/01 |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 69 | 28/16/28 | |
David Bejker
BRD | Director/Board Member | 49 | 27/17/27 |
Eskil Elmér
FOU | Founder | 54 | 01/00/01 |
Roger Franklin
BRD | Director/Board Member | 45 | 20/20/20 |
Denise Goode
BRD | Director/Board Member | 66 | 27/18/27 |
| Director/Board Member | 64 | 27/17/27 |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 1,056,299,165 | 930,212,762 ( 88.06 %) | 0 | 88.06 % |
Company contact information
Sector
| 1st Jan change | Capi. | |
|---|---|---|
| +11.91% | 12TCr | |
| +11.60% | 11TCr | |
| -4.68% | 2.43TCr | |
| -0.82% | 2.2TCr | |
| -10.12% | 1.82TCr | |
| -42.12% | 1.64TCr | |
| -17.47% | 1.56TCr | |
| +2.77% | 1.36TCr | |
| +34.67% | 1.23TCr |
